Investigational drug · Phase 3
FT-4202
Also called: Etavopivat
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Sickle Cell Disease, Thalassemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
4 still active
All registered trials
5
Any phase or sponsor naming "FT-4202"
First trial start
2021
Jan 29, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FT-4202", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sickle Cell Disease
- Thalassemia
Approved drugs for the same conditions: Sickle cell disease · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "FT-4202" as an intervention, largest first.
- A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)Pivotal-lookingActive, not recruiting
Forma Therapeutics, Inc.Industry
NCT04624659 · 450 participants (planned) · Start Jan 29, 2021 · Primary completion Feb 6, 2026
Drug: Etavopivat Tablets Low dose; Etavopivat Tablets High dose and 2 more · For: Sickle Cell Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease PatientsPivotal-lookingCompleted
Forma Therapeutics, Inc.Industry
NCT03815695 · 130 participants · Start Dec 11, 2018 · Primary completion Dec 17, 2021
Drug: FT-4202/Placebo · For: Healthy Volunteers; Sickle Cell Disease
Sites: Little Rock, Arkansas; Long Beach, California; Oakland, California · 18 sites in all
Forma Therapeutics, Inc.Industry
NCT04987489 · 53 participants · Start Mar 28, 2022 · Primary completion Sep 3, 2025
Drug: Etavopivat tablets · For: Sickle Cell Disease; Thalassemia
Sites: Cerritos, California; Los Angeles, California; Oakland, California · 32 sites in all
- A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)Terminated
Forma Therapeutics, Inc.Industry
NCT05568225 · 17 participants · Start Nov 15, 2022 · Primary completion Jul 15, 2024
Drug: Etavopivat · For: Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
Sites: Miami, Florida; Ocala, Florida; New York, New York · 10 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05725902 · 12 participants · Start Mar 9, 2024 · Primary completion Mar 9, 2026
Drug: Etavopivat · For: Sickle Cell Disease
Sites: Atlanta, Georgia
Newest research
PubMed records naming it or its code names, newest first.
- 2026 Update on Clinical Trials in β-Thalassemia.
Musallam KM, Locatelli F, Algeri M, et al. · Am J Hematol 2026
- Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease.
Musallam KM, Andemariam B · Hemoglobin 2026
- The pyruvate kinase activator etavopivat (FT-4202) limits pulmonary and systemic sequelae of sepsis in a mouse LPS model.
Chen Y, Zhu H, Zhang L, et al. · Am J Physiol Lung Cell Mol Physiol 2026
- FT-4202, a selective pyruvate kinase R activator for sickle cell disease.
Ericsson A, Richard DJ, Wilker E, et al. · Exp Hematol 2025
- Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.
Saraf SL, Hagar R, Idowu M, et al. · Blood Adv 2024
- Quantitative Model-Based Assessment of Multiple Sickle Cell Disease Therapeutic Approaches Alone and in Combination.
Moody AT, Narula J, Maurer TS · Clin Pharmacol Ther 2024
Also in development for Sickle Cell Disease
- Exa-celPhase 31 trial
Vertex Pharmaceuticals · Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- TebapivatAG-946Phase 22 trials
Agios Pharmaceuticals, Inc. · Myelodysplastic Syndromes, Sickle Cell Disease
- AnumigilimabPhase 21 trial
CSL Behring · Sickle Cell Disease
- BEAM-101Phase 21 trial
Beam Therapeutics Inc. · Sickle Cell Disease
- ITU512Phase 21 trial
Novartis · Sickle Cell Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.